logo-loader

Medivation

Receive alerts
Market:
NASDAQ
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases, for which there are limited treatment options. Its product candidates in clinical development are MDV3100, which is in Phase 3 development for the treatment of advanced prostate cancer, and dimebon (latrepirdine), which is in Phase 3 development for the treatment of Alzheimer’s disease and Huntington disease. Its MDV3100 program is partnered with Astellas Pharma Inc. (Astellas, and its dimebon program is partnered with Pfizer Inc. (Pfizer).